This might include one or more of the following medications: dulaglutide (Trulicity) exenatide (Bydureon) liraglutide (Victoza, Saxenda) lixisenatide (Adlyxine) semaglutide (Ozempic, Rybelsus, Wegovy) These are GLP-1 receptor agonists that the FDA has approved for conditions such as: managing type 2 diabetes obesity fatty liver disease improving cardiovascular health However, more research is needed to determine whether they may be effective in treating OSA
using an Asian cohort, which may reflect differences in diabetes management, baseline cardiovascular risk, and genetic predisposition to amputation
Anyone comparing options while Retatrutide continues through further research can review established treatments through resources like Wegovy or Ozempic, and explore broader context through guides such as Retatrutide side effects or Retatrutide vs tirzepatide
Class C (Generally acceptable, still disclose): Supplements with no known pharmacodynamic overlap, including magnesium glycinate, zinc, and probiotics
The peptide increases the potential for melanogenesis, and the UV light acts as the trigger to activate it